Clinical Trial

Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome

Study acronym: HUCMSC
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated December 31, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of Alport syndrome (AS) in a randomized, single-blind, placebo-controlled trial, to provide a clinical basis for the development of stem cell products for the treatment of AS, and to further clarify the therapeutic effect of hUC-MSC in the treatment of AS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-09.
Trial Details
NCT Number NCT06731192
Lead Sponsor Guangzhou Women and Children's Medical Center
Conditions Alport Syndrome
Enrollment 40 participants
Start Date 2025-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-31